Polymethine Dye Liver Targeting for PKC Inhibitors in Septic Cholestasis

The patent applies local quality by modifying the chemical structure of PKC inhibitors to include a polymethine dye moiety (such as indocyanine green) that confers liver-specific targeting capability. This allows the drug to selectively accumulate in the liver tissue where it is needed to treat cholestasis, while minimizing systemic distribution and immune suppression effects. The local concentration of the drug in the liver is enhanced through passive targeting via the enhanced permeability and retention effect and active targeting through hepatocyte-specific uptake mechanisms.

The patent employs an intermediary approach by using polymethine dye-conjugated PKC inhibitors as a bridge between systemic administration and liver-specific action. The polymethine dye acts as a mediator that directs the drug to the liver through its affinity for hepatocytes and its accumulation in liver tissue. This intermediary structure enables the drug to reach the target organ selectively without requiring direct injection into the liver, thus maintaining the therapeutic effect while reducing systemic side effects.

The patent achieves local quality by designing PKC inhibitors with polymethine dye moieties that selectively accumulate in the liver. This structural modification enables the drug to concentrate in the target organ at therapeutic doses that are lower than what would be required for systemic treatment. The liver-specific accumulation is achieved through passive targeting via the enhanced permeability and retention effect and active targeting through hepatocyte-specific uptake mechanisms, thereby reducing the overall drug dose needed while maintaining therapeutic efficacy.

The patent applies parameter changes by modifying the pharmacokinetic parameters of PKC inhibitors through conjugation with polymethine dyes. This structural modification alters the distribution, accumulation, and clearance characteristics of the drug, enabling selective liver targeting. The changed parameters include increased liver tissue concentration, extended residence time in the liver, and reduced systemic exposure, all of which contribute to improved therapeutic efficacy at lower doses with reduced adverse effects.

The patent applies local quality by conjugating polymethine dyes (such as indocyanine green) to PKC inhibitors, which imparts liver-specific targeting properties to the drug. This structural modification enables the inhibitor to selectively accumulate in liver tissue through passive targeting via the enhanced permeability and retention effect and active targeting through hepatocyte-specific uptake mechanisms. The local concentration in the liver is enhanced while systemic distribution is minimized, thereby maintaining the simple PKC inhibition mechanism while reducing systemic side effects.

The patent employs composite materials by creating hybrid molecules that combine PKC inhibitor pharmacophores with polymethine dye moieties. This composite structure integrates the therapeutic function of PKC inhibition with the targeting function of polymethine dyes that have affinity for hepatocytes. The composite molecule exhibits both the biochemical activity of the inhibitor and the tissue-specific distribution properties of the dye, achieving liver-selective therapy while maintaining mechanistic simplicity.